Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2006 Oct;5(10):864-76.

Signalling platforms that modulate the inflammatory response: new targets for drug development.

Author information

1
CIHR Group in Matrix Dynamics, University of Toronto, Toronto, Canada M5S 3E2. christopher.mcculloch@utoronto.ca

Abstract

Therapeutically controlling inflammation is essential for the clinical management of many high-prevalence human diseases. Drugs that block the pro-inflammatory cytokines tumour-necrosis factor-alpha and interleukin-1 (IL-1) can improve outcomes for rheumatoid arthritis and other inflammatory diseases but many patients remain refractory to treatment. Here we explore the need for developing new types of anti-inflammatory drugs and the emergence of novel drug targets based on the clustering of IL-1 receptors into multi-protein aggregates associated with cell adhesions. Interference with receptor aggregation into multi-protein complexes effectively abrogates IL-1 signalling. The exploration of the crucial molecules required for receptor clustering, and therefore signal transduction, offers new targets and scope for anti-inflammatory drug development.

PMID:
17016427
DOI:
10.1038/nrd2109
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center